Gastric cancer
Conditions
Interventions
Experimental group:Paclitaxel(Albumin-bound)
Sponsors
Gansu Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients over 18 years old; 2. Patients with HER2 negative gastric cancer or cancer at the gastroesophageal junction confirmed histologically; 3. Ct3-4bn + MX in patients with operative local progression or potential resectable metastasis; 4. Tumor size can be measured according to the evaluation standard of solid tumor response (recist1.1 standard); 5. KFS score >= 70; 6. Bone marrow function: neutrophil >= 1.5 x 10^9 / L, platelet >= 100 x 10^9 / L, hemoglobin >= 90g / L; 7. Liver and kidney function: serum creatinine <= 1.5 times the upper limit of normal value; AST and alt <= 2.5 times the upper limit of normal value; total bilirubin <= 1.5 times the upper limit of normal value; 8. Patients who have good compliance with the planned treatment, can understand the research process of this study and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have received radiotherapy or chemotherapy before; 2. Patients with squamous cell carcinoma of the gastroesophageal junction; 3. Patients with uncontrolled hypertension, congestive heart failure or myocardial infarction within six months; 4. Patients with any other malignancies in the past 5 years; 5. Patients with untreated central nervous system diseases or symptomatic central nervous system metastasis diseases; 6. Patients with upper gastrointestinal obstruction or abnormal physiological function, or with malabsorption syndrome, may affect S-1 absorption; 7. Pregnancy or lactation, and childbearing age patients who refuse to take appropriate contraceptive measures during the course of this trial; 8. Patients who need immunosuppressive therapy for organ transplantation; 9. Patients with uncontrolled severe infection or other serious concomitant diseases 10. Patients not suitable for this study were judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathology complete remission, pCR;objective remission rate, ORR;R0 resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS;overall survival, OS;Adverse Events; | — |
Countries
China
Contacts
Public ContactDa Mingxu
Department of Oncology, Gansu Provincial Hospital
Outcome results
None listed